U.S. FDA Grants Priority Review to Takeda's Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to the New Drug Application (NDA) for ixazomib, the first investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma.
Source: International Myeloma Foundation - Category: Hematology Source Type: news
More News: Food and Drug Administration (FDA) | Grants | Hematology | Myeloma | New Drug Applications